期刊文献+

抗阿尔茨海默病Aβ人-鼠嵌合抗体基因的真核载体构建和表达 被引量:2

Vector construction and expression of anti-Aβ human-mouse chimeric antibody against Alzheimer's disease
原文传递
导出
摘要 目的 通过基因工程抗体技术构建和表达抗β-淀粉样多肽(Aβ)人-鼠嵌合抗体,减低鼠源单克隆抗体在临床应用中引起的人体免疫排斥反应.方法从分泌抗Aβ1-42鼠单克隆抗体杂交瘤细胞株中提取总RNA,用逆转录-聚合酶链反应(RT-PCR)扩增鼠源性抗体全长基因,并通过Blast对其序列进行分析;利用重组PCR技术拼接重轻链可变区及人IgG1的恒定区基因,并对重链Fc段进行定点突变以降低排斥反应;分别构建人-鼠嵌合基因重轻链表达载体,用脂质体法将其同时导入COS-7细胞中表达,并利用ELISA和免疫组织化学(SP法)对分泌的抗体功能和性质进行初步鉴定.结果 Blast比对分析结果显示克隆的基因序列符合小鼠抗体基因序列,将可变区基因与人IgG1的恒定区基因拼接以及Fc定点突变后,成功构建了嵌合抗体的真核表达载体,并实现真核表达;ELISA和免疫组织化学方法证实了所分泌抗体的人源性和与Aβ的结合特异性.结论成功地构建和表达了抗阿尔茨海默病Aβ人-鼠嵌合抗体,为其在阿尔茨海默病的临床诊治中应用和进一步改造奠定了基础. Objectives To construct and to express a human-mouse chimeric antibody against Aβ peptide involved in Alzheimer disease by genetic antibody engineering with reducing of its human anti-mouse antibody response. Methods Total RNA was extracted from a murine hybridoma cell line that secreted anti- Aβ monoclonal antibody. The entire gene coding heavy and light chains were amplified using RT-PCR and analyzed by Genebank Blast. The chimeric antibody gene was acquired by variable region gene of the monoclonal antibody with constant region gene of human IgG, in which point mutations were incluced by recombinant PCR technology, respectively. The eukaryotic expression vectors established by cloning chimeric antibody genes of the heavy and light chains into 3. 1 were co-transfected into COS-7 cells. The expressed products were analyzed using ELISA and immunohistochemistry subsequently. Results Genebank Blast analysis showed that the entire cloned antibody genes were in accordance with the murine antibody genes. DNA sequencing confirmed that the expression vectors of chimeric antibody were constructed successfully after splicing the variable region and constant region sequences. By co-transfecting COS-7 cells, a chimeric antibody was produced and collected in the culture medium. The antibody was humanized and bound Aβ specifically by ELISA and immunohistochemistry evaluations. Conclusions Expression vector of chimeric antibody against Aβ was constructed successfully and expressed in the eukaryotic cells. It provides a solid base for developing diagnostic and therapeutic methods for Alzheimer's disease in clinic and paves a way for a further humanization in the future.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2010年第8期542-547,共6页 Chinese Journal of Pathology
关键词 阿尔茨海默病 抗体 单克隆 淀粉样Β蛋白 Alzheimer disease Antibodies monoclonal Amyloid beta-protein
  • 相关文献

参考文献16

  • 1Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics.Science,2002,297(5580):353-356.
  • 2McLaurin J,Cecal R,Kierstead ME,et al.Therapeutically effective antibodies against amyloid-beta peptide target amyloidbeta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.Nat Med,2002,8(11):1263-1269.
  • 3贾静,刘喆,赵雪梅,梁平.抗阿尔茨海默病Aβ人源单链抗体基因的筛选和表达[J].中华病理学杂志,2008,37(6):400-404. 被引量:3
  • 4Carter P,Presta L,Gorman CM,et al.Humanization of an antip185HER2 antibody for human cancer therapy.Proc Natl Acad Sci U S A,1992,89(10):4285-4289.
  • 5Selkoe DJ.Alzheimer' s disease:genes,proteins,and therapy.Physiol Rev,2001,81(2):741-766.
  • 6Solomon B.Immunotherapeutic strategies for Alzheimer's disease treatment.Scientific World Journal,2009,9:909-919.
  • 7Weiner HL,Frenkel D.Immunology and immunotherapy of Alzheimer's disease.Nat Rev Immunol,2006,6(5):404-416.
  • 8Karlnoski RA,Rosenthal A,Kobayashi D,et al.Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice.J Neurosci,2009,29 (15):4964-4971.
  • 9Almagro JC,Fransson J.Humanization of antibodies.Front Biosci,2008,13:1619-1633.
  • 10Gonzales NR,De Pascalis R,Schlom J,et al.Minimizing the immunogenicity of antibodies for clinical application.Tumour Biol,2005,26(1):31-43.

二级参考文献12

  • 1夏骏,李晓宇,陈秀英,范乐明,陈琪.β淀粉样多肽人源性抗体的筛选与鉴定[J].南京医科大学学报(自然科学版),2004,24(4):328-331. 被引量:3
  • 2蔡炯,王世真,彭勇,钟彦伟,姬志娟,袁建刚,强伯勤.阿尔茨海默病Aβ人抗体可变区片段基因的克隆和表达[J].中国医学科学院学报,2003,25(5):557-562. 被引量:6
  • 3DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral. anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 2001, 98(15) :8850-8855.
  • 4Frost D, Gorman PM, Yip CM, et al. Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. Eur J Biochem, 2003, 270(4): 654-663.
  • 5Legleiter J, Czilli DL, Gitter B, et al. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol, 2004, 335(4) : 997-1006.
  • 6Geylis V, Steinitz M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev, 2006, 5 ( 1 ) : 33-39.
  • 7Clark M. Antibody humanization: a case of the ‘Emperor's new clothes'? Immunol Today, 2000, 21 (8):397-402.
  • 8Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol, 2005, 23(9): 1105-1116.
  • 9Solorzano-Vargas RS, Vasilevko V, Acero G, et al. Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42. Mol Immunol, 2008,45 (4) : 881-886.
  • 10Manoutcharian K,Acero G, Munguia ME, et al. Human single chain Fv antibodies and a complementarity determining regionderived peptide binding to amyloid-beta 1-42. Neurobiol Dis, 2004,17(1) : 114-121.

共引文献2

同被引文献24

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部